Lord, Abbett & Co
ALNY icon

Lord, Abbett & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lord, Abbett & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,406
Closed -$14.1M – 563
2025
Q4 		$14.1M Sell
35,406
-31,814
-47% -$14.1M 0.04% 327
2025
Q3 		$30.7M Buy
+67,220
New +$27.4M 0.09% 231
2023
Q1 		– Sell
-523,972
Closed -$125M – 543
2022
Q4 		$125M Buy
523,972
+4,840
+0.9% +$1.03M 0.45% 51
2022
Q3 		$104M Buy
+519,132
New +$99M 0.38% 68
2022
Q1 		– Sell
-42,000
Closed -$7.12M – 602
2021
Q4 		$7.12M Sell
42,000
-238,000
-85% -$44.2M 0.02% 527
2021
Q3 		$52.9M Buy
+280,000
New +$52.5M 0.13% 250
2018
Q2 		– Sell
-297,210
Closed -$35.4M – 843
2018
Q1 		$35.4M Buy
297,210
+40,408
+16% +$5.21M 0.11% 302
2017
Q4 		$32.6M Buy
256,802
+141,050
+122% +$17.7M 0.09% 337
2017
Q3 		$13.6M Buy
+115,752
New +$9.88M 0.04% 557
2015
Q3 		– Sell
-133,584
Closed -$16M – 901
2015
Q2 		$16M Sell
133,584
-209,734
-61% -$25.1M 0.04% 542
2015
Q1 		$35.8M Buy
343,318
+59,027
+21% +$5.98M 0.09% 345
2014
Q4 		$27.6M Sell
284,291
-407,656
-59% -$37.8M 0.07% 394
2014
Q3 		$54M Sell
691,947
-51,724
-7% -$3.34M 0.14% 195
2014
Q2 		$47M Buy
743,671
+601,719
+424% +$35.8M 0.11% 271
2014
Q1 		$9.53M Sell
141,952
-177,610
-56% -$13.8M 0.02% 656
2013
Q4 		$20.6M Sell
319,562
-264,543
-45% -$15.8M 0.05% 525
2013
Q3 		$37.4M Sell
584,105
-442,397
-43% -$22.1M 0.09% 341
2013
Q2 		$31.8M Buy
+1,026,502
New +$27.3M 0.07% 399

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lord, Abbett & Co's ALNY Position: Q1 2026 in Review

Lord, Abbett & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 35,406 shares — an estimated $14.1M sold.

Lord, Abbett & Co first reported a position in ALNY in Q2 2013 and held it in 18 quarters. The position peaked at $125M in Q4 2022. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Lord, Abbett & Co reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Lord, Abbett & Co sold 35,406 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $14.1M.
  • Lord, Abbett & Co first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Lord, Abbett & Co's Alnylam Pharmaceuticals position peaked at $125M in Q4 2022.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.